[[TAKEAWAYS]] - Structure Therapeutics is building a pipeline around G‑protein coupled receptors (GPCRs), a major class of drug targets with high therapeutic potential. - Analysts see the company as a “hidden multibagger” because its early‑stage assets could unlock significant upside if they reach the clinic. - The current crypto market is in a state of extreme fear (fear‑greed index 21), meaning risk‑seeking assets like biotech are often priced lower than their fundamentals would suggest. - For retail crypto holders, adding a biotech play can provide diversification away from the volatility of digital assets. - Key catalysts